Page last updated: 2024-11-13
f-chemotactic peptide-fluorescein
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 44152507 |
MeSH ID | M0171743 |
Synonyms (9)
Synonym |
---|
117576-09-7 |
f-chemotactic peptide-fluorescein |
l-lysine, n6-(((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3h),9'-(9h)xanthen)-4(or 5)-yl)amino)thioxomethyl)-n2-(n-(n-(n-(n-(n-formyl-l-norleucyl)-l-leucyl)-l-phenylalanyl)-l-norleucyl)-l-tyrosyl)- |
n-formylnorleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl-lysyl-fluorescein |
n-formyl-nle-leu-phe-nle-tyr-lys-fluorescein |
fnlpntl-fluorescein |
DTXSID40151828 |
(2s)-6-[(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4-yl)carbamothioylamino]-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-formamidohexanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl] |
n6-((3',6'-dihydroxy-3-oxo-3h-spiro[isobenzofuran-1,9'-xanthen]-4-yl)carbamothioyl)-n2-(((s)-2-((s)-2-((s)-2-((s)-2-formamidohexanamido)-4-methylpentanamido)-3-phenylpropanamido)hexanoyl)-l-tyrosyl)-l-lysine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |